was forecast by lying management!2006: $28+ high when Torcetrapib approval was forecast by management.2007: $27+ high likely to hold, given decelerating, low, low single digit growth, if any. At least no new high above 2006's should be expected.
Also in 2005, all PFE's recent pipeline disappointments were also in the future, like Indiplon & Exubera, among so many others.No way can PFE possibly ever trade over $29 again in this decade. Even if revenues pick up in 2009, with Lipitor out in 2010, it's not gonna happen.India & China are a joke. They'll never use branded drugs, or at least not pay for them. They'll make their own generics, as Ranbaxy does.Americans have been pinning their false hopes on the "China trade" for over 200 years without any success, except for fur otter traders in the 1790s & opium traders in the 1830s.
Oh, also keep in mind that PFE could easily start aquiring other companies in order to grow it's product offerings.
PFE is a slow growth stock with a fat yield. SHould break $30 by decades end though ... it's not that bad.